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Abstract 
  
 RanBPM/RanBP9 is a multi-domain nucleocytoplasmic protein which has 
been linked to numerous cellular processes including cell adhesion, migration, 
transcription and apoptosis. Although RanBPM is a member of the mammalian 
CTLH complex, the counterpart of a conserved yeast E3 ubiquitin ligase complex, its 
exact function remains unknown. Previous work in our laboratory has shown that 
RanBPM inhibits the ERK pathway by interacting with the kinase c-Raf and 
downregulating c-Raf levels. Here, we show that the N-terminus, LisH/CTLH and 
CRA domains of RanBPM are required for downregulation of c-Raf and that 
RanBPM interacts directly with c-Raf through its CRA domain. We also provide 
evidence that MAEA, another CTLH complex member, associates with c-Raf. 
Therefore, we propose a mechanism by which RanBPM downregulates c-Raf in a 
CTLH complex-dependent manner. This work contributes to our knowledge of the 
function of RanBPM and clarifies the relationship between RanBPM and c-Raf, two  
important proteins in oncogenesis. 
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Chapter 1 – Introduction 
1.1. Cancer 
 According to the Canadian Cancer Society, it is estimated that 
approximately 267,400 Canadians will be diagnosed with cancer in 2014, with 
the most common types being prostate, breast, lung, colorectal and non-
melanoma skin cancer (1). Cancer is the leading cause of death in Canada, with 
an estimated 1 in 4 Canadians expected to die from the disease (1). Therefore, it 
is evident that cancer research focused on understanding the disease and 
developing new treatments to combat tumour growth are of utmost importance to 
preserve the health of our population. 
 Although the average one gram malignant tumour is estimated to contain 
108–109 cancer cells, such tumour masses can start with the defiant behaviour of 
a single cell (2). Cells are programmed to grow, replicate and die when they have 
reached the end of their lifespan, however a cell can break free from these 
restraints in the event of genomic mutation and proliferate uncontrollably, 
resulting in cellular transformation and tumourigenesis. Cancer cells exhibit 
certain characteristics, termed the hallmarks of cancer, which are acquired during 
cellular transformation and are predominantly responsible for the progression of 
the disease (3). Namely, they sustain proliferative signaling, evade signaling from 
growth suppressors, resist cell death, replicate infinitely, induce angiogenesis 
and invade surrounding tissues (3).  
 Understanding the cellular and molecular processes behind each of these 
hallmarks is key in understanding how a healthy cell transforms into a malignant 
cell, and ultimately contributes valuable knowledge that can be used to generate 
novel therapies to fight cancer. This thesis aims to contribute to this pool of 
knowledge by studying the relationship between RanBPM (Ran-binding protein 
M) and c-Raf (rapidly accelerating fibrosarcoma), two proteins known to play 
roles in critical cellular processes which, when perturbed, can lead to the 
development of the hallmarks of cancer. 
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 1.2. RanBPM 
1.2.1. Overview of RanBPM 
RanBPM, also known as RanBP9, was initially discovered in a yeast two-
hybrid assay as a 55kDa interacting partner for the small guanosine 
triphosphatase (GTPase), Ran (Ras-related nuclear protein) (4). However, 
subsequent studies soon uncovered that RanBPM is in fact a 90kDa protein, only 
weakly interacts with Ran and does not localize to the centrosome, as initially 
thought (4,5). Since then, RanBPM has generated significant interest and 
numerous studies have been conducted on the protein to attempt to characterize 
its function.  
RanBPM is widely conserved across mammals, with over 96% similarity 
between human and mouse RanBPM, although homologs are also present in 
many other species (6). In mammals, RanBPM has been shown to be 
ubiquitously expressed, with higher expression in heart, muscle, brain and 
reproductive tissues (7,8). RanBPM was initially recovered in a 670kDa complex 
and, since then, its involvement in complex formation has been described 
extensively (5,9). It has been shown to interact with countless proteins and be 
implicated in a variety of cellular processes including, but not limited to, 
transcription, cell adhesion, cell migration and apoptosis (9). Although a 
considerable number of studies have identified proteins that interact with 
RanBPM (Table 1.1), a large portion of them lack insight on the functional 
significance of the interactions (9). For these reasons, RanBPM has widely been 
hypothesized to be a scaffolding protein, however, its exact function still remains 
unknown (9).  
2
Table 1.1. Comprehensive list of proteins that have been shown to interact 
with RanBPM. Methods used to demonstrate the interactions are indicated as yeast 
two-hybrid (Y2H), mammalian two-hybrid (M2H), pull-down (PD), 
immunoprecipitation (IP), proximity ligation assay (PLA), confocal microscopy (CM) 
and/or fluorescence resonance energy transfer (FRET).  
 
Interacting proteins Methods 
Domains of  
RanBPM required 
References 
RanBPM IP ND (13) 
p73 Y2H, PD, IP ND (17) 
CDK11
p46 Y2H, PD, IP, CM SPRY (20) 
p75NTR Y2H, IP ND (21) 
HIPK2 Y2H, IP, CM ND (22) 
c-Raf PD, IP, PLA CRA (24), present study 
L1 Y2H, PD, IP SPRY (25) 
MET Y2H, M2H, PD, IP SPRY (8) 
TrkB IP, CM ND (26) 
APP IP SPRY/LisH (29) 
BACE1 IP SPRY/LisH (29) 
LRP IP SPRY/LisH (29) 
FMRP Y2H, PD, IP, CM CRA (14) 
plexin-A Y2H, IP ND (34) 
TrkA Y2H, PD, IP SPRY (35) 
TAF4 Y2H, IP, CM ND (36) 
AR Y2H, PD, IP SPRY (7) 
TR Y2H, PD, IP ND (37) 
LFA-1 Y2H, PD, IP ND (39) 
β1 integrin Y2H, IP ND (39) 
BLT-2 Y2H, PD, IP, CM ND (43) 
BRCA1 Y2H ND (44) 
Muskelin Y2H, IP ND (42,46) 
Twa1 Y2H, IP, PD ND (42,46) 
Rmnd5a IP ND (46) 
MAEA IP ND (46) 
ARMc8 IP ND (46) 
HDAC6 IP, CM LisH/CTLH (103) 
TRAF6 Y2H, PD, IP, CM, FRET ND (107) 
USP11 Y2H, IP SPRY (109) 
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1.2.2. Conserved domains 
Four conserved functional domains have been identified within the 
sequence of RanBPM: the SplA and Ryanodine receptor (SPRY) domain, the 
Lissencephaly type-1-like homology (LisH) domain, the C-terminal to LisH 
(CTLH) domain and the CT11-RanBPM (CRA) domain (Figure 1.1) (10). The 
SPRY domain is known to be involved in protein-protein interactions (11). The 
LisH domain is known to mediate protein dimerization, and is in fact predicted to 
moderate the dimerization and oligomerization of RanBPM (12,13). Additionally, 
the LisH domain, together with the CTLH domain, is thought to regulate 
microtubule dynamics and cell migration (12). The CRA domain, which is 
predicted to contain six α-helices and resembles a death domain (DD) 
superfamily domain, has also been shown to function as a protein interaction 
surface (14). In addition to these four conserved domains, RanBPM also contains 
a proline- and glutamine-rich N-terminus predicted to contain six Src homology 3 
(SH3) binding domains (5,15). 
 
1.2.3. Cellular localization 
Although RanBPM was initially thought to be localized to the centrosome, 
further studies determined its localization to actually be predominantly 
nucleocytoplasmic (4,5). Recent studies in our laboratory have identified a 
primary nuclear localization signal (NLS) spanning amino acids 1–25, a 
secondary NLS spanning amino acids 635–649 and a nuclear export signal 
(NES) comprising amino acids 140–155, which together govern the subcellular 
localization of RanBPM (16). The SPRY and LisH/CLTH domains were also 
shown to be important for cytoplasmic retention of RanBPM, potentially through 
interactions with cytoplasmic proteins (16).  
Indeed, the subcellular localization of RanBPM has previously been 
shown to be influenced by interactions with other proteins. For example, 
overexpression of p73 was shown to promote the translocation of RanBPM from 
4
  
 
 
 
Figure 1.1. Full-length RanBPM with conserved domains indicated. RanBPM 
contains a SPRY domain (amino acids 212–333), a LisH/CTLH domain (amino acids 
367–460) and a CRA domain (amino acids 615–729). 
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the cytoplasm to the nucleus (17). Given that these two proteins physically 
interact and p73 is exclusively nuclear, it was hypothesized that an 
overabundance of p73 could sequester a high proportion of cellular RanBPM in 
the nucleus (17). Furthermore, under certain cellular conditions, RanBPM 
localization has been reported to be altered. For example, in response to ionizing 
radiation (IR), a DNA damage-inducing agent, RanBPM has been shown to 
shuttle from the nucleus to the cytoplasm (18). This change in localization could 
occur to allow RanBPM to interact with cytoplasmic apoptotic or DNA damage 
response proteins, although this speculation has yet to be confirmed (18). 
Altogether, such evidence suggests that RanBPM localization is important in 
dictating its function, as it allows RanBPM to interact with various specifically 
compartmentalized proteins and participate in different signaling pathways.  
 
1.2.4. Role in apoptosis 
 
Although the specific function of RanBPM has yet to be elucidated, there 
is substantial evidence that it plays an important role in the activation of 
apoptosis. RanBPM has been shown to interact with the tumour-suppressor 
protein p73 and enhance its apoptotic activity (17). The interaction between 
these two proteins was demonstrated to be required for the ability of RanBPM to 
activate apoptosis, induce mitochondrial membrane permeability, decrease levels 
of the anti-apoptotic protein Bcl-2 (B cell lymphoma 2), increase levels of the pro-
apoptotic protein Bax and enhance Bax oligomerization (19). It has also been 
demonstrated that, through its SPRY domain, RanBPM interacts with and is 
phosphorylated by CDK11p46 (cyclin-dependent kinase 11), a caspase-cleaved 
C-terminal kinase segment of the larger CDK11p110 isoform (20). Caspase-
cleavage of CDK11p110 occurs during apoptosis and cleaved CDK11p46 continues 
to propagate apoptotic signals, potentially through a RanBPM-dependent 
mechanism (20). RanBPM has also been shown to interact with the pro-apoptotic 
neurotrophin receptor p75NTR (p75 neurotrophin receptor) through its 
intracellular DD and to interact with the nuclear protein kinase HIPK2 
6
  
(homeodomain-interacting protein kinase 2), which has been shown to activate 
and stabilize the tumour-suppressor protein p53 (21-23). 
Important studies in our laboratory have demonstrated that RanBPM 
activates apoptosis in response to DNA damage caused by IR (18). Subsequent 
studies showed that RanBPM is in fact an inhibitor of the ERK (extracellular 
signal-regulated kinase) pathway and specifically downregulates the crucial ERK 
pathway kinase c-Raf at the protein level (24). This resulted in decreased 
downstream ERK pathway signaling, culminating in decreased levels of the anti-
apoptotic protein Bcl-2 and its family member Bcl-XL (B cell lymphoma extra 
large) (24). This is consistent with previous findings that RanBPM regulates the 
intrinsic cell death pathway (19). In addition, it was found that downregulation of 
RanBPM leads to increased cell proliferation, an important hallmark of cellular 
transformation and cancer (24). 
Other studies have also shown that RanBPM restricts ERK pathway 
signaling. For example, through its SPRY domain, it was observed that an N-
terminal fragment of RanBPM interacts with the neural adhesion molecule L1 to 
inhibit downstream ERK signaling (25). Although it appears that RanBPM is a 
pro-apoptotic protein that inhibits the ERK pathway, there is some opposing 
evidence that RanBPM activates the ERK pathway through interactions with the 
receptor tyrosine kinases TrkB (tropomyosin-related kinase B) and MET 
(mesenchymal epithelial transition factor), although the latter was shown using a 
green fluorescent protein (GFP) tagged RanBPM construct (8,26). Therefore, 
some of the contradiction regarding RanBPM regulation of the ERK pathway 
could potentially be attributed to the different constructs used in each study and 
the unknown effects of large tags or truncations on the overall function of 
RanBPM.  
 
1.2.5. Functions in the reproductive and nervous systems 
 
Numerous studies have demonstrated roles for RanBPM in the 
reproductive and nervous systems, but nowhere is this more evident than in the 
7
  
characterization of RanBPM knockout mice. It is well documented that RanBPM 
knockout mice generally die neonatally, although a small number of newborn 
pups have been reported to survive into adulthood (27,28). The cause of this 
neonatal fatality remains unclear, although it has been suggested that these pups 
are unable to suckle milk, suggesting defects in brain function (28). RanBPM 
knockout mice suffer pronounced gonadal atrophy, severely compromised 
spermatogenesis and oogenesis as well as infertility, provided they reach 
adulthood (27). Furthermore, they display growth retardation and their brains are 
dramatically reduced in size, especially in the hippocampal and cortical regions, 
compared to wild-type (WT) mice (28). 
A number of important studies have also implicated RanBPM in the 
development of the neurodegenerative disorder Alzheimer’s disease (AD). 
Interestingly, a truncated form of RanBPM has been shown to be expressed over 
six times higher in the brains of AD patients compared to those of healthy 
individuals (13). One of the defining pathological hallmarks of AD is the 
accumulation of Aβ (amyloid β) peptides in the brain and RanBPM has been 
shown to promote Aβ generation from its precursor APP (amyloid precursor 
protein) (29). RanBPM accelerates endocytosis of APP and acts as a scaffold for 
APP, BACE1 (β-secretase 1) and the endocytosis receptor LRP (low-density 
lipoprotein receptor-related protein) to facilitate BACE1 cleavage of APP into Aβ 
(29). Consistent with previously mentioned evidence regarding RanBPM 
involvement in apoptosis, these studies have shown that RanBPM 
overexpression causes apoptosis and also potentiates Aβ toxicity in the brain 
(30). In addition, RanBPM transgenic mice suffered neurodegeneration, spatial 
memory loss and a decreased number of neuronal synapses (31). 
RanBPM has been shown to interact with proteins involved in other 
neurodegenerative diseases as well. RanBPM interacts with FMRP, a protein 
whose loss of expression leads to the most common form of hereditary mental 
retardation, fragile X syndrome (32). FMRP is an RNA-binding protein 
predominantly found in neurons and spermatogonia that regulates translation 
and transport of mRNA (32,33). Through its CRA domain, RanBPM directly binds 
8
  
and sequesters the RNA-binding region of FMRP, rendering it unable to execute 
its RNA-binding function (14). RanBPM has also been reported to interact with 
the neural adhesion molecule L1, which can lead to various X-linked disorders if 
mutated (9). Inhibition of ERK signaling by an N-terminal fragment of RanBPM 
suppresses L1-meditated neurite outgrowth and branching in primary neurons 
(25). 
Further functions for RanBPM in the nervous system include interaction 
with the plexin-A receptor to inhibit axonal outgrowth and induce neuronal 
contractility (34). RanBPM also been shown to interact with the receptor tyrosine 
kinases TrkB and TrkA, which both serve as neurotrophin receptors in the brain 
(26,35). Through its interaction with TrkB, RanBPM was shown to enhance 
neuronal morphogenesis, and through its interaction with TrkA, RanBPM was 
shown to reduce downstream expression of the transcription factor NFAT 
(nuclear factor of activated T cells), which is known to play a role in axon 
outgrowth and synaptic plasticity (26,35). 
 
1.2.6. Regulation of transcriptional activity 
 
RanBPM has further been suggested to regulate transcriptional activity in 
the cell. RanBPM has been shown to interact with TAF4 (transcription initiation 
factor TFIID subunit 4), a subunit of the general transcription factor TFIID 
(transcription factor II D) (36). TFIID is a member of the RNA polymerase II 
preinitation complex that binds the TATA box during the initial steps of gene 
transcription. The interaction between RanBPM and TAF4 was demonstrated to 
initiate primary neurite branching in neuronal stem cells, although the 
transcriptional model by which this occurs has yet to be elucidated (36). 
Furthermore, RanBPM has been reported to interact with the ligand-dependent 
transcription factors AR (androgen receptor) and TR (thyroid hormone receptor) 
and enhance their transcriptional activities (7,37). RanBPM can also augment the 
transcriptional activity of GR (glucocorticoid receptor), although an interaction 
between the two proteins has not explicitly been shown (7). 
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Microarray analyses in our laboratory have shown that RanBPM 
influences transcriptional pathways primarily associated with cell, tissue and 
organ development as well as tumorigenesis and cancer (38). Upon RanBPM 
downregulation, global gene expression changes occurred and over-represented 
transcription factor binding sites were identified among the upregulated or 
downregulated genes (38). Among the most over-represented were binding sites 
for the Forkhead, homeodomain and HMG (high mobility group) transcription 
factors, providing further evidence that RanBPM regulates transcription by 
modulating transcription factor activity (38). 
 
1.2.7. Implications in cell morphology, adhesion and migration 
 
There is evidence of RanBPM involvement in cell morphology and polarity, 
based on its reported interactions with known regulators of these processes. It 
has been reported that RanBPM interacts with β1 integrin and the β2 integrin 
LFA-1 (lymphocyte function-associated antigen-1) (39,40). Integrins are 
transmembrane receptors that are well-known for mediating cell-cell and cell-
extracellular matrix interactions through focal adhesions, however, they also 
participate in many signaling pathways within the cell (39). RanBPM has been 
shown to accelerate endocytosis of β1 integrin to disrupt integrin-dependent cell 
adhesion, focal adhesion assembly and focal adhesion signaling (40). Some data 
also suggests that RanBPM acts in conjunction with Muskelin to regulate cell 
morphology and cell spreading, as they are found together in a complex and 
knockdown of either Muskelin or RanBPM in lung epithelial cells led to the same 
phenotype of increased cell perimeter and disrupted actin distribution (41,42). 
Studies in our laboratory have found that RanBPM also inhibits cell 
migration, as downregulation of RanBPM increased cell migration in human 
embryonic kidney (HEK) cells (24). These findings are compatible with previous 
studies showing that RanBPM interacts with the G protein coupled receptor BLT2 
(leukotriene B4 receptor 2) and reduces BLT2-mediated cell migration (43). 
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1.2.8. RanBPM in cancer 
 
 Evasion of apoptosis, sustained proliferative signal and tissue invasion 
mark three of the six primary hallmarks of cancer demonstrated by malignant 
cells (3). Given its prominent roles in apoptosis as well as restricting cell growth 
and cell migration, it has been suggested that RanBPM might be playing a role in 
the prevention of tumour development and oncogenesis. As previously 
mentioned, RanBPM has been shown to interact with many pro-apoptotic tumour 
suppressors, inhibit proliferative cell pathways and directly induce apoptosis in 
response to DNA damage (17-25). It has also been shown to interact with 
proteins involved in cell motility and directly inhibit cell migration (24,43). 
Interestingly, RanBPM expression has been found to be altered in many human 
tumours, including lung, kidney and breast cancer samples (39). In most cases, 
expression was lost or greatly reduced, validating its characterization as a 
tumour suppressor protein (39).  
 RanBPM has also been identified in a high-throughput yeast two-hybrid 
screen searching for proteins that interact with the C-terminal region of BRCA1 
(breast cancer type 1 susceptibility protein), a DNA damage repair tumour 
suppressor primarily expressed in breast and ovarian tissues (44). Individuals 
with mutations in BRCA1 are undoubtedly considered to be at high risk to 
develop breast cancer. Although the functional significance behind the interaction 
between RanBPM and BRCA1 was not elucidated, the interaction itself further 
suggests roles for RanBPM in DNA damage control and tumour suppressive 
activity. Additionally, a breast cancer single nucleotide polymorphism (SNP) was 
identified a short distance upstream of the RanBPM gene at nucleotide position 
13830502 on chromosome 6 (45). Though the specific impact of this SNP on 
RanBPM expression or function has not been determined, this finding implies 
that RanBPM may be involved in cancer development and specifically in breast 
cancer development. 
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1.2.9. CTLH complex 
 
RanBPM is a known member of the mammalian CTLH complex, along 
with Muskelin, Twa1 (two hybrid-associated protein 1 with RanBPM), Rmnd5a 
(required for meiotic nuclear division 5 homolog A), MAEA (macrophage 
erythroblast attacher) and ARMc8 (armadillo repeat containing 8) (42,46). Each 
of these proteins, with the exception of Muskelin, have orthologs in 
Saccharomyces cerevisiae which are part of the yeast Gid (glucose induced 
degradation deficient) complex (Figure 1.2) (6). Gid1, the ortholog of RanBPM, 
acts as a crucial scaffold in this complex and primarily mediates interactions with 
other Gid proteins through its LisH and CTLH domains (Figure 1.3) (47). The Gid 
complex has been shown to function as an E3 ubiquitin ligase (48). In general, 
E3 ubiquitin ligases are key components of the ubiquitin-protease system (UPS) 
and act in concert with E1 activating enzymes and E2 ubiquitin conjugating 
enzymes to ubiquitinate target proteins and send them for degradation through 
the proteasome (49). The Gid complex specifically targets FBPase (fructose-1,6-
bisphosphatase) for proteasome-mediated degradation when glucose becomes 
available and FBPase is no longer needed for yeast to perform gluconeogenesis 
(48). Although the Gid complex is a proven E3 ubiquitin ligase in yeast, it is 
unknown if the CTLH complex performs a similar function in mammalian cells (6).  
However, there has been some evidence of members of the CTLH complex 
playing a role in the ubiquitination and degradation of proteins. ARMc8 has been 
shown to bind HRS (Hepatocyte growth factor-regulated tyrosine kinase 
substrate) and promote its association with ubiquitinated proteins (50). ARMc8 
has also been implicated in the proteasome-dependent degradation of α-catenin, 
although this was shown to occur independently of ubiquitination (51). 
Furthermore, both Rmnd5a and MAEA possess a Really Interesting New Gene 
(RING) domain, which is a defining characteristic of many E3 ubiquitin ligases 
(6). In fact, evidence suggests that Rmnd5a and its paralog, Rmnd5b, have E3 
ubiquitin ligase activity as both have been shown to associate with E2 ubiquitin 
12
 Figure 1.2. Mammalian orthologs of the members of the S. cerevisiae Gid 
complex. Proteins found within the Gid complex are represented on the right, along 
with their respective mammalian orthologues represented on the left. Conserved 
domains are indicated and members of the mammalian CTLH complex are denoted 
with an asterisk. Adapted from (6).  
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Figure 1.3. Model of the interactions between members of the S. cerevisiae Gid 
complex. Gid1, Gid2, Gid4, Gid5, Gid7, Gid8 and Gid9 interact to form an E3 
ubiquitin ligase, with the ortholog of RanBPM, Gid1, serving as a central scaffold in 
the complex. Orthologs of Gid proteins that are also found in the mammalian CTLH 
complex are indicated in italics. Adapted from (47).  
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conjugating enzymes and promote the ubiquitination of the prostatic tumour 
suppressor NKX3.1 (52). 
 
1.3. c-Raf 
 
1.3.1. Overview of Raf family kinases 
 
The Raf family of serine/threonine kinases have been a hot topic of 
research since the discovery of the first raf gene, retroviral oncogene v-raf, in 
1983 (53). Mammalian isoforms A-Raf, B-Raf and c-Raf soon generated interest 
due to their crucial role as signaling molecules in the ERK pathway, a pathway 
known to play an important role in many crucial cellular processes and whose 
loss of regulation can be devastating to an organism (54-56). Given that the ERK 
pathway is upregulated in approximately one-third of all human cancers (56), it 
has become clear that understanding Raf protein function is critical in 
understanding the ERK pathway as a whole and its role in cancer development.  
The structure of all three mammalian Raf kinases (Figure 1.4) can be 
divided into a regulatory N-terminal region and a catalytic C-terminal region. The 
N-terminus contains a primary Ras (rat sarcoma) binding site and a cysteine-rich 
secondary Ras binding site (54). The C-terminus contains a negative-charge 
regulatory region (N-region) and an activation segment, both containing multiple 
phosphorylation sites required for Raf activation (54,57), as well as an adenosine 
triphosphate (ATP) binding domain. Numerous regulatory phosphorylation sites, 
both activating and inhibitory, are also found throughout Raf (54).  
A-Raf, B-Raf and c-Raf are all ubiquitously expressed in mammals (58), 
although A-Raf and B-Raf levels have been found to be higher in urogenital 
organs and neuronal tissues, respectively (59-61). Although all three kinases 
have been shown to participate in ERK signaling (54), evidence suggests that the 
isoforms also perform additional non-redundant functions. A-Raf knockout mice 
tend to die 7–21 days after birth due to neurological and gastrointestinal 
deficiencies (62), whereas c-Raf and B-Raf knockout mice die in utero from a 
15
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Structure, conserved regions and regulatory phosphorylation sites 
of Raf family kinases. (A) General structure of the Raf kinases with conserved 
regions indicated. (B) Specific structures of A-Raf, c-Raf and B-Raf with activating 
phosphorylation sites (red), inhibitory phosphorylation sites (black), phosphorylation 
sites defined as both activating and inhibitory (blue) and autophosphorylation sites 
(green) indicated. Adapted from (54). 
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different set of complications (63,64). Although both types of mice demonstrate 
growth retardation, c-Raf knockout mice exhibit liver defects while B-Raf 
knockout mice exhibit vascular and neuronal deficiencies (63,64). Given the 
different phenotypes observed in these knockout mice and the apparent lack of 
compensation between Raf isoforms, and it is clear that A-Raf, B-Raf and c-Raf 
function differently despite their relatively conserved structure.  
B-Raf, which is the strongest ERK pathway activator of the Raf family, has 
most recently generated interest due to the discovery of common oncogenic 
mutations in tumours, such as V600E (54). This mutation mimics phosphorylation 
of an activating site within the protein, resulting in a constitutively active form of 
B-Raf and persistent ERK pathway signaling (65). Prior to this discovery, 
however, c-Raf, the 70kDa isoform also known as Raf-1, was the primary isoform 
under investigation and thus still remains one of the best characterized Raf 
kinases (54). 
 
1.3.2. ERK signaling pathway 
 
As previously mentioned, Raf is an important component of the ERK 
signaling pathway (Figure 1.5). Overall, the ERK pathway has been reported to 
regulate numerous cellular processes, including cell survival, differentiation, 
proliferation, motility, transcription and metabolism (54,55). To summarize 
signaling within the pathway, cell membrane embedded receptor tyrosine kinases 
(RTKs) are first activated by extracellular ligands and autophosphorylation occurs 
on the intracellular domains of the receptors (54). The guanine nucleotide 
exchange factor SOS (son of sevenless) and the adaptor protein Grb2 (adaptor 
protein growth factor receptor-bound protein 2) are subsequently recruited to the 
phosphorylated intracellular domains of the receptor (54). SOS activates the cell 
membrane-linked protein Ras by exchanging its guanosine diphosphate (GDP) 
for guanosine triphosphate (GTP) (54). Activated Ras initiates a cascade of 
phosphorylation events where Ras activates Raf, which promotes the activation 
of MEK1/2 (mitogen-activated protein kinase kinase 1/2), which finally activates 
17
 Figure 1.5. Summary of ERK pathway signaling. Extracellular signals promote 
RTK activation and autophosphorylation. Intracellular Grb2 and SOS are recruited to 
the phosphorylated receptor, and subsequently promote the exchange of GDP for 
GTP on membrane-bound Ras. Activated Ras initiates a cascade of activating 
phosphorylation events involving Raf, MEK and ERK, respectively. Activated ERK 
has countless substrates in both the cytoplasm and nucleus, including the 
transcription factor CREB which, when activated, induces transcription of anti-
apoptotic factors Bcl-2 and Bcl-XL.  
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ERK1/2 (54). Phosphorylated active ERK1/2 has over 150 reported targets in the 
cell, both nuclear and cytoplasmic (54,66).  
For example, one of the outcomes of ERK1/2 phosphorylation is the 
activation of the transcription factor CREB (cAMP response element-binding 
protein) and the subsequent increase in transcription of certain anti-apoptotic 
factors, such as Bcl-2 and Bcl-XL (67). Other well-known targets of ERK1/2 
include the transcription factors Elk1 (ETS domain-containing protein) and c-Fos 
(cellular FBJ murine osteosarcoma viral oncogene homolog), the kinases DAPK 
(death associated protein kinase) and MSK1/2 (mitogen- and stress-activated 
protein kinases 1/2) and the cytoskeletal element paxillin (66). 
Furthermore, a number of scaffolding proteins have been shown to 
interact with components of the ERK pathway to facilitate signaling. The best-
characterized scaffolds include KSR1 (kinase suppressor of Ras 1) and the 
IQGAP (IQ motif containing GTPase-activating protein) family of proteins, 
although there are many other scaffolds that have been reported to localize ERK 
pathway signaling to various compartments within the cell (55). 
 
1.3.3. MEK1/2-independent signaling by c-Raf 
 
Although it has been argued that MEK1/2 is the only Raf substrate 
(54,58), there is also emerging evidence that Raf is able to regulate a number of 
signaling molecules independent of the ERK pathway. Given that B-Raf is the 
primary Raf isoform involved in MEK1/2 activation, it has been suggested that c-
Raf and A-Raf have evolved other functions (54,68). For example, adenylyl 
cyclases (ACs) 2, 5 and 6 have been reported to be phosphorylated and 
activated by c-Raf (69,70). Given that PKA deactivates c-Raf, and PKA is 
indirectly activated by ACs, activation of ACs by c-Raf would appear to contribute 
to negative feedback regulation of c-Raf. Rb (retinoblastoma tumour suppressor 
protein) has also been shown to be a phosphorylation target of c-Raf, an event 
which leads to the inactivation of Rb and consequential cell cycle progression 
(71).  
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Although c-Raf is a well-characterized kinase, it also affects signaling of 
some proteins in a kinase-independent manner. For instance, the pro-apoptotic 
proteins ASK1 (apoptosis signal-regulating kinase 1) and MST2 (mammalian 
Ste20-like kinase 2) are negatively regulated through direct binding with c-Raf 
(72,73). Rok-α (Rho-binding kinase α) is also inhibited solely by c-Raf binding, a 
phenomenon that regulates cell motility and protects against apoptosis (74,75). 
 
1.3.4. c-Raf activation and deactivation 
 
Due to the aforementioned implications of deregulation of the ERK 
pathway, c-Raf activity is tightly controlled. Regulation of c-Raf activity is a 
complex process that involves a number of proteins and many phosphorylation 
and dephosphorylation events.  In an inactive state, the N-terminus of c-Raf is 
folded over and stabilized by a 14–3–3 protein dimer in a conformation that 
masks the C-terminus (Figure 1.6A) (76). 14–3–3 specifically interacts with c-Raf 
on two phosphorylated residues, S259 and S621 (77). To activate c-Raf, S259 is 
dephosphorylated by phosphatases PP2A (protein phosphatase 2A) and PP1 
(protein phosphatase 1) and 14–3–3 is released from this binding site (Figure 
1.6B) (78). Conformational changes occur which displace the N-terminal 
regulatory domain of c-Raf from the C-terminal catalytic domain, thus revealing 
the primary and secondary Ras binding sites previously sequestered within c-Raf 
(Figure 1.6C) (79). Ras is allowed to bind c-Raf and kinases are recruited to 
phosphorylate activating sites on c-Raf (Figure 1.6D). These sites include several 
sites in the activation segment as well as S338, S339, Y340 and Y341 in the N-
region (80,81). Phosphorylation of amino acids 338–341 is essential for full c-Raf 
activation and also for interaction with its substrate MEK1/2 (82). PAK1 (p21-
activated kinase 1), JAK2 (Janus kinase 2), Src (sarcoma) and CK2 (casein 
kinase 2) have each been reported to phosphorylate a subset of these residues 
(76,83,84), although there are likely other kinases involved that have yet to be 
identified (54). A number of other phosphorylation sites have been reported to 
enhance c-Raf activity (54) and c-Raf heterodimerization with B-Raf has also 
20
 Figure 1.6. Summary of the activation cycle of c-Raf. (A) The N-terminal 
regulatory region of c-Raf (light blue) sequesters the C-terminal catalytic region (dark 
blue) in a closed inactive conformation stabilized by 14–3–3 (orange). The 
interaction between c-Raf and 14–3–3 is stabilized by the phosphorylated residues 
(black) S259 and S621 on c-Raf. (B) S259 is dephosphorylated and 14–3–3 is 
released from the c-Raf N-terminus, creating a semiclosed inactive conformation. 
(C) c-Raf adapts an open inactive conformation, where the N-terminus unmasks the 
C-terminus and binds membrane-bound Ras (green). (D) The C-terminus of c-Raf is 
phosphorylated on a number of residues, leading to an open active form of the 
protein. Adapted from (79). 
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been proposed to increase kinase activity compared to monomeric or 
homodimeric versions of either protein (85). 
During c-Raf deactivation, the phosphorylated N-region serves as a 
binding site for RKIP (Raf kinase inhibitor protein) (86), which dissociates 
MEK1/2 from c-Raf (87). PP5 (protein phosphatase 5) binds c-Raf and promotes 
the dephosphorylation of S338 (88) while PP2A dephosphorylates other 
activating sites (89). PKA (protein kinase A) has also been reported to contribute 
to c-Raf deactivation, phosphorylating S43 and S233, which interfere with Ras 
binding, as well as S259, which interferes with Ras binding and contributes to 
14–3–3 binding (90,91). Altogether, these events return c-Raf to its inactive state, 
stabilized in a closed conformation by 14–3–3.  
 
1.3.5. Regulation of c-Raf stability 
 
In addition to the abundance of phosphorylation and dephosphorylation 
events that regulate c-Raf activity, there are also some systems known to 
regulate c-Raf stability and overall c-Raf levels within the cell. One well-known 
regulator of c-Raf stability is the chaperone protein Hsp90 (heat shock protein 
90). Hsp90 is a highly conserved molecular chaperone that mediates the folding 
of newly synthesized or misfolded client proteins, assembles and disassembles 
molecular complexes and prevents protein aggregation (92). Hsp90 does not 
perform these tasks alone, however, as it has been shown to form complexes 
with over 20 co-chaperones (92).  
Although Hsp90 generally functions to help rescue client proteins, it has 
also been shown to form a complex with Hsp70 (heat shock protein 70), another 
molecular chaperone, and CHIP (C-terminus of Hsp70-interacting protein), an E3 
ubiquitin ligase, to target terminally misfolded proteins for ubiquitination and 
degradation by the proteasome (92,93). Hsp90 has been shown to bind and 
stabilize the tertiary structure of c-Raf, allowing it to localize to the membrane, 
interact with Ras and properly engage in ERK pathway signaling (94-96). 
Disruption of binding between the two proteins results in proteasomal 
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degradation of c-Raf (97). There has been evidence that CHIP is able to 
ubiquitinate c-Raf, suggesting that CHIP is an E3 ubiquitin ligase responsible for 
proteasomal degradation of the kinase (98,99). XIAP (X-linked inhibitor of 
apoptosis), a member of the IAP (inhibitor of apoptosis) family of proteins, has 
been shown to be a modulator of CHIP-mediated c-Raf degradation. Although 
XIAP itself is an E3 ubiquitin ligase, evidence suggests that XIAP interferes with 
c-Raf stability and promotes recruitment of CHIP to Hsp90 and c-Raf, 
independently of its ubiquitin ligase activity (99).  
There has also been evidence of c-Raf degradation by mechanisms that 
do not rely on CHIP. It has been reported that autophosphorylation of S621 is 
necessary for c-Raf stabilization, as kinase-dead mutants were ubiquitinated and 
targeted to the proteasome (100). This occurred even when CHIP levels were 
knocked-down by siRNA, suggesting that other E3 ubiquitin ligases may also 
play a role in c-Raf downregulation (100). c-Raf has also been shown to be 
ubiquitinated and degraded by the proteasome in response to disruption of cell 
adhesion and treatment with the oxidative glucose metabolite methylglyoxal, 
however the mechanisms by which these events occurred were not determined 
(101,102). 
Studies conducted in our laboratory have shown that c-Raf is 
downregulated by RanBPM, as shRNA-mediated RanBPM knock-down led to 
increased c-Raf protein levels and re-expression of RanBPM reversed this effect 
(24). Downregulation was observed for both endogenous c-Raf and transfected 
constitutively active c-Raf, but the effect was more prominent on the latter (24). 
RanBPM shRNA knock-down also led to increased levels of Bcl-2, Bcl-XL, 
phosphorylated ERK1/2 and phosphorylated MEK1/2 and re-expression of 
RanBPM reversed these effects in multiple cell lines (24). This suggests that, 
through its effect on c-Raf, RanBPM is an inhibitor of the ERK pathway. These 
studies further demonstrated, via immunoprecipitation and pull-down assays, that 
RanBPM is found in a complex with endogenous c-Raf and can also form a 
complex with constitutively active c-Raf, consisting only of the catalytic region of 
the protein (24). RanBPM was also shown to disrupt c-Raf association with 
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Hsp90, providing insight on a potential mechanism by which c-Raf could be de-
stabilized by RanBPM (24). However, further studies exploring this concept have 
yet to be conducted and other mechanisms could also contribute to c-Raf 
downregulation by RanBPM. 
 
1.4. Hypothesis and objectives 
 
Work in our laboratory has shown that RanBPM and c-Raf are found 
together in a complex and that RanBPM downregulates c-Raf at the protein level 
(24). However, how the two proteins interact and the mechanism by which 
RanBPM downregulates c-Raf remains unknown. Therefore, it is hypothesized 
that specific domains of RanBPM are required for direct interaction with c-Raf 
and regulation of c-Raf stability by a mechanism that could involve the CTLH 
complex. The work presented in this thesis aims to specifically address the 
following objectives: 
 
(1) Determine which domain(s) of RanBPM are required for regulation of c-
Raf stability. 
(2) Identify which domain(s) of RanBPM are required for interaction with c-
Raf. 
(3) Investigate the possibility of CTLH complex involvement in c-Raf 
downregulation. 
 
It has become evident that investigating the key mechanisms that tightly 
regulate the activity and stability of the components of the ERK pathway, namely 
c-Raf, is critical in understanding the devastating consequences associated with 
the loss of regulation of this pathway and can contribute to the development of 
new therapies to combat cancer. Furthermore, in light of the recent identification 
of RanBPM as an activator of apoptosis, a better understanding of its effect on c-
Raf will help elucidate its role as a critical tumour suppressor. Overall, the work 
presented in this thesis clarifies the relationship between two important proteins 
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that play critical roles in cell growth, differentiation, apoptosis and cancer 
development. 
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Chapter 2 – Materials and Methods 
 
2.1. Chemicals and reagents 
 
All enzymes and buffers used for cloning were obtained from either New 
England Biolabs Inc. (Ipswich, MA, USA) or Fermentas Thermo Fisher Scientific 
Inc. (Waltham, MA, USA) and were used according to the manufacturer’s 
protocol. Hydrochloric acid (HCl) was also acquired from Thermo Fisher 
Scientific Inc. Fetal bovine serum (FBS), trypsin, L-glutamine, sodium pyruvate, 
paraformaldehyde (PFA), sodium chloride (NaCl), ethylenediaminetetraacetic 
acid (EDTA), hydroxyethyl piperazineethanesulfonic acid (HEPES), sodium 
dodecyl sulfate (SDS), Tris-hydroxymethyl amino methane (Tris) and potassium 
chloride (KCl) were purchased from Wisent Inc. (St. Bruno, QC, Canada), while 
Dulbecco’s modified eagle medium (DMEM) and phosphate buffered saline 
(PBS) were purchased from both Gibco by Life Technologies Inc. (Burlington, 
ON, Canada) and Wisent Inc. G418 sulphate, Triton X-100, Nonidet P-40 
(NP40), aprotinin, leupeptin, pepstatin, dithiothreitol (DTT), sodium fluoride 
(NaF), sodium orthovanadate (NaVO4), pheylmethylsulfonyl fluoride (PMSF) and 
isopropyl β-D-1-thiogalactopyranoside (IPTG) were purchased from BioShop Inc. 
(Burlington, ON, Canada) while glycerol was acquired from Caledon Laboratory 
Chemicals Ltd. (Georgetown, ON, Canada).  
 
2.2. Antibodies 
 
Primary antibodies used were RanBPM (K-12, sc-46253 and F-1, sc-
271727, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), c-Raf (E-10, sc-
7267 and C-12, sc-133, Santa Cruz Biotechnology Inc.), β-actin (I-19, sc-1616-R, 
Santa Cruz Biotechnology Inc.), human influenza hemagglutinin (HA) (HA-7, 
H3663, Sigma-Aldrich Inc., Oakville, ON, Canada), glutathione-S-transferase 
(GST) (B-14, sc-138, Santa Cruz Biotechnology Inc.), Hsp90 α/β (H-114, sc-
7947, Santa Cruz Biotechnology Inc.) and MAEA (ab65239, Abcam Inc., 
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Cambridge, MA, USA). For each application, primary antibodies were used in the 
concentrations indicated in Table 2.1. 
Secondary antibodies used for Western blot analyses were Peroxidase-
conjugated AffiniPure Goat anti-Mouse IgG (H+L) (Jackson ImmunoResearch 
Laboratories Inc., West Grove, PA, USA) and Blotting Grade Goat anti-Rabbit 
IgG (H+L) (Human IgG Adsorbed) Horseradish Peroxidase Conjugate (Bio-Rad 
Laboratories Inc., Mississauga, ON, Canada). Both were used at a concentration 
of 1:5000. 
 
2.3. Plasmid constructs 
 
pCMV-HA-RanBPM was a gift from Dr. Mark Nelson (University of 
Arizona, Tucson, AZ, USA) and was rendered resistant to shRNA degradation 
via the introduction of two silent point mutations as described in (18). RanBPM 
deletion mutants pCMV-HA-RanBPM-ΔN2, pCMV-HA-RanBPM-ΔC4, pCMV-HA-
RanBPM-ΔC1, pCMV-HA-RanBPM-Δ212, and pCMV-HA-RanBPM-Δ360 were 
generated as described in (18,103). pEBG-GST-ΔN-c-Raf was a gift from Dr. 
Zhijun Luo (Boston University, Boston, MA, USA). 
pET28a-ΔN-c-Raf was generated by isolating a fragment encoding ΔN c-
Raf from pEBG-GST-ΔN-c-Raf using BamHI and NotI, and ligating into the 
bacterial expression vector pET28a (EMD Millipore, Billerica, MA, USA) using T4 
DNA ligase. pGEX4T1-GST-WT-RanBPM, pGEX4T1-GST-N2-domain and 
pGEX4T1-GST-C1-domain were generated by polymerase chain reaction (PCR) 
amplifying full-length WT RanBPM, RanBPM amino acids 1–102 or RanBPM 
amino acids 649–729, respectively, from pCMV-HA-RanBPM. PCR was 
performed using KOD Hot Start Polymerase PCR kit (EMD Millipore) according 
to the manufacturer’s protocol. Primers used for PCR are outlined in Table 2.2. 
PCR products were subsequently digested with BamHI and SalI-HF and were 
each ligated into the bacterial expression vector pGEX-4T-1 (GE Healthcare Life 
Sciences, Little Chalfont, Buckinghamshire, UK) using T4 DNA ligase. 
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Table 2.1. Concentrations of primary antibodies used for Western blot and in 
situ proximity ligation assay. 
 
Antibody Species 
Western blot 
concentration 
In situ proximity ligation 
assay concentration 
RanBPM (K-12) goat N/A 1:400 
RanBPM (F-1) mouse N/A 1:50 
c-Raf (E-10) mouse 1:500 1:50 
c-Raf (C-12) rabbit 1:500 N/A 
β-actin (I-19) rabbit 1:2000 N/A 
HA (HA-7) mouse 1:1000 N/A 
GST (B-14) mouse 1:500 N/A 
Hsp90 α/β (H-114) rabbit N/A 1:100 
MAEA (ab65239) rabbit N/A 1:200 
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Table 2.2. PCR primer sequences and descriptions. 
 
Primer Tm Sequence (5’ to 3’) Description 
RBPMfwdBamHI 70.1°C GCTAGGATCCATGTCCGGGCAGCCGCCG 
forward PCR 
primer to amplify 
WT RanBPM 
and N2 domain 
RBPMrevSalI 65.6°C CGCGGTACGTCGACTAATGTAGGTAGTCTTCC 
reverse PCR 
primer to amplify 
WT RanBPM 
and C1 domain 
N2domrevSalI 68.8°C GTATGTCGACTACCCGCTGGCGGGGGC 
reverse PCR 
primer to amplify 
N2 domain 
C1domfwdBamHI 64.3°C CGATGGATCCAAGGATGCATTCAGTCTACTAGC 
forward PCR 
primer to amplify 
C1 domain 
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2.4. Stable shRNA cell lines and cell culture 
 
HeLa cells were obtained from the American Type Culture Collection 
(Manassus, VA, USA). HeLa cell lines stably expressing either RanBPM shRNA 
(clone 2-7) or control shRNA were generated as described in (18). HeLa 2-7 cells 
and HeLa control cells were cultured in DMEM supplemented with 8% FBS, 1% 
sodium pyruvate, 1% L-glutamine, 4.5g/L glucose and 0.35g/L G418 sulphate at 
37°C in 5% CO2. Cells were washed with PBS and detached with trypsin upon 
passaging. 
 
2.5. In situ proximity ligation assay 
 
To prepare for the Duolink II in situ proximity ligation assay (PLA) (Sigma-
Aldrich Inc.), cover slips were pre-treated by outlining with the hydrophobic 
ImmEdge pen (Vector Laboratories Inc., Burlingame, CA, USA). HeLa cells were 
seeded on these cover slips at approximately 50,000 cells per cover slip, fixed 
with 4% PFA for 13 minutes at 4°C, permeabilized with 0.5% Triton X-100 for 10 
minutes at room temperature, and blocked for 1 hour with 5% FBS in PBS at 
room temperature. Cover slips were incubated in the appropriate primary 
antibodies at the concentrations indicated in Table 2.1 overnight at 4°C. 
Manufacturer’s instructions were followed for the in situ PLA. Cover slips were 
mounted onto glass slides with Prolong Gold antifade reagent with DAPI 
(Molecular Probes by Life Technologies, Burlington, ON, Canada) and were 
subsequently analyzed at 358nm (nucleus) and either 555nm or 647nm 
(fluorescent oligonucleotide probe) with an Olympus BX51 microscope (Olympus 
America Inc., Center Valley, PA, USA) using a 40x objective. Images were 
captured using Image-Pro Plus v4.5 software (Media Cybernetics Inc., Bethesda, 
MD, USA). 
 
 
 
30
  
2.6. Transfection assays 
 
ExGen 500 in vitro Transfection Reagent (Fermentas Thermo Fisher 
Scientific Inc.), TurboFect Transfection Reagent (Thermo Fisher Scientific Inc.) 
and JetPRIME Transfection Reagent (PolyPlus Transfection, Illkirch, France) 
have all been used according to the manufacturer’s instructions for transfection 
of HeLa cells. For each pCMV-HA RanBPM deletion mutant, the amount of 
construct transfected was adjusted to account for variations in stability between 
the expressed proteins. In all cases, the amount of DNA used was brought up to 
the manufacturer’s recommendations with the vector pBS-SK (Agilent 
Technologies, Santa Clara, CA, USA). Transfected cells were incubated 24–48 
hours at 37°C in 5% carbon dioxide (CO2). 
 
2.7. Preparation of mammalian cell extracts 
 
HeLa cells were scraped in cold PBS, centrifuged at 8000rpm for 3 
minutes, lysed for 40 minutes on ice in whole cell extract (WCE) buffer (150mM 
NaCl, 1mM EDTA, 50mM HEPES pH 7.4 and 10% glycerol) and supplemented 
with 0.5% NP40, 0.5% Triton X-100, 10μg/mL aprotinin, 2μg/mL leupeptin, 
2.5μg/mL pepstatin, 1mM DTT, 2mM NaF, 2mM NaVO4, and 0.1mM PMSF. The 
lysate was centrifuged at 13,000rpm for 20 minutes at 4°C and the resulting 
supernatant was collected. 
 
2.8. Bacterial protein expression and preparation of Escherichia coli 
extracts 
 
For each bacterial expression construct, plasmids were transformed into 
E. coli strain BL21DE3. Single transformants were selected and grown in Luria 
Bertani (LB) medium overnight at 37°C. This culture was diluted 1:150 into fresh 
LB medium and grown to an optical density at 600nm (OD600) between 0.4–0.5. 
Protein expression was induced with 0.1mM IPTG and the culture was incubated 
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overnight at 16°C. Bacteria was centrifuged at 4000rpm for 20 minutes at 4°C 
and subsequently resuspended in lysis buffer (25mM HEPES pH 7.4, 10mM KCl, 
2mM EDTA and 20% glycerol) supplemented with 0.1% NP40, 10μg/mL 
aprotinin, 2μg/mL leupeptin, 2.5μg/mL pepstatin, 1mM DTT, 2mM NaF, 2mM 
NaVO4, and 0.1mM PMSF. The cell suspension was sonicated three times for 10 
seconds on ice using the Sonic Dismembrator Model 100 (Thermo Fisher 
Scientific Inc.), centrifuged at 13,000rpm for 10 minutes at 4°C and the resulting 
supernatant was collected. 
 
2.9. Western blot analyses 
 
Samples were resolved by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) on either 8% or 10% acrylamide gels and 
subsequently transferred for either for 1 hour at 100V or overnight at 25V onto a 
polyvinylidene fluoride (PVDF) membrane. Blots were blocked in 5% non-fat dry 
milk for at least 1 hour at room temperature, then incubated in primary antibody 
diluted in 5% non-fat dry milk as indicated in Table 2.1 overnight at 4°C or for 1 
hour at room temperature. Blots were incubated in secondary antibody diluted in 
5% non-fat dry milk for 1 hour at room temperature and developed using either 
Western Lightning Enhanced Chemiluminescence (ECL) Substrate (Perkin Elmer 
Inc., Waltham, MA, USA) or Clarity Western ECL Substrate (Bio-Rad 
Laboratories Inc.). Images were captured using either Kodak X-OMAR LS film 
(Carestream Health Inc., Rochester, NY, USA) or the ChemiDoc MP (Bio-Rad 
Laboratories Inc.) and Image Lab software (Bio-Rad Laboratories Inc.). 
 
2.10. GST pull-down assays 
 
2.10.1. Using HeLa cell extracts 
 
Extracts were quantified and 1800μg total protein was aliquoted for each 
pull-down sample. Extracts were brought up to 1mL with WCE buffer to a final 
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concentration of 0.4% NP40, 0.4% Triton X-100, 20μg/mL aprotinin, 4μg/mL 
leupeptin, 5μg/mL pepstatin, 2mM DTT, 4mM NaF, 4mM NaVO4, and 0.2mM 
PMSF. Glutathione-Agarose beads (Sigma-Aldrich Inc.) suspended in PBS were 
added to each sample to a final concentration of 5μL beads/100μg total protein 
and pull-down samples were incubated overnight at 4°C. Beads were 
subsequently washed three times in WCE buffer supplemented with 0.4% NP40, 
0.4% Triton X-100, 1mM DTT and 0.1mM PMSF. Beads were resuspended in 
SDS loading dye (0.105g/mL SDS, 0.093g/mL DTT, 0.35M Tris HCl pH 6.8 and 
30% glycerol), boiled for 5 minutes and centrifuged at 10,000rpm for 10 seconds. 
The resulting supernatant was collected and analyzed by Western blot. 
 
2.10.2. Using E. coli extracts 
 
Extracts were quantified and, for each GST-tagged construct, 
approximately 400μg total protein was used for each pull-down sample. Samples 
were brought up to 200μL with lysis buffer and subsequently brought up to 600μL 
with binding buffer (15mM HEPES pH 7.4, 6mM KCl, 1.2mM EDTA and 12% 
glycerol) to a final concentration of 0.6% NP40, 0.6% Triton X-100, 10μg/mL 
aprotinin, 2μg/mL leupeptin, 2.5μg/mL pepstatin, 1mM DTT, 2mM NaF, 2mM 
NaVO4, and 0.1mM PMSF. Samples were incubated for 2 hours at 4°C with 30μL 
Glutathione-Agarose beads. Beads were washed three times with binding buffer 
supplemented with 0.6% NP40, 0.6% Triton X-100, 1mM DTT and 0.1mM PMSF. 
Each sample was then incubated with 200μg ΔN c-Raf extract and brought up to 
800μL with binding buffer to a final concentration of 0.6% NP40, 0.6% Triton X-
100, 10μg/mL aprotinin, 2μg/mL leupeptin, 2.5μg/mL pepstatin, 1mM DTT, 2mM 
NaF, 2mM NaVO4, and 0.1mM PMSF. Samples were again incubated for 2 hours 
at 4°C and beads were washed with binding buffer supplemented with 0.6% 
NP40, 0.6% Triton X-100, 1mM DTT and 0.1mM PMSF. Beads were 
resuspended in SDS loading dye, boiled for 5 minutes and centrifuged at 
10,000rpm for 10 seconds. The resulting supernatant was collected and 
analyzed by Western blot. 
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2.11. Statistical analyses 
 
Using Microsoft Office Excel 2007 (Microsoft Corporation, Redmond, WA, 
USA), one-way analysis of variance (ANOVA) was performed to compare 
multiple groups and two-sample t-test assuming unequal variance was performed 
to compare pairs of groups. Graphed data are presented as mean ± standard 
error of the mean (SEM) and are determined to be significant when p < 0.05. The 
number of independent replicates for each experiment is denoted as N. 
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Chapter 3 – Results 
 
3.1. Endogenous RanBPM and c-Raf are found in a complex 
 
Previous co-immunoprecipitation and pull-down experiments in our 
laboratory have demonstrated that RanBPM and c-Raf exist together in a 
complex (24). Since this was shown using ectopically expressed protein 
constructs, we sought to confirm that the complex occurs with the endogenous 
proteins in cells. The in situ PLA, an assay that allows visualization of protein-
protein interactions in cells using fluorescence microscopy (Figure 3.1) (104), 
was thus used to visualize the interaction between endogenous RanBPM and c-
Raf in HeLa cells.  
To summarize the PLA, fixed and permeabilized cells are incubated with 
primary antibodies against two proteins of interest. Two types of specialized 
secondary antibodies fused to short DNA strands, called PLA probes, are then 
incubated with the cells to bind their respective primary antibodies. When two 
different PLA probes come within 40nm of each other, the DNA strands are 
ligated together and amplified by a polymerase in a process termed rolling-circle 
amplification. The amplified DNA product is then hybridized with a fluorescently 
labeled complementary oligonucleotide probe, which is then visualized by 
fluorescence microscopy. Each fluorescent dot seen represents a protein-protein 
interaction between the two proteins of interest.  
Stable HeLa cell lines expressing either a control or RanBPM shRNA 
(clone 2-7), which were previously generated in our laboratory (18), were used in 
this experiment. To ensure the PLA probes did not confer any background signal, 
a control was performed where HeLa control cells were incubated without 
primary antibodies. To gauge the specificity of the RanBPM primary antibody, 
another control was included where HeLa 2-7 cells were incubated with primary 
antibodies against RanBPM and c-Raf. As expected, fluorescent dots 
representing interactions were not observed in either negative control (Figures 
3.2A and 3.2B).  
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Figure 3.1. Summary of the in situ PLA. Primary antibodies against two proteins of 
interest are incubated with fixed and permeabilized cells. Secondary antibodies 
attached to short DNA strands, called PLA probes, are incubated with the cells and 
allowed to bind the primary antibodies. When two PLA probes come within 40nm of 
each other, ligation with special oligonucleotides anneal the two PLA probe DNA 
strands and allow them to form a circle. This circle of DNA is amplified using a 
polymerase, and this amplified product is hybridized with a fluorescently labeled 
oligonucleotide probe. Each protein-protein interaction is represented as a 
fluorescent dot which can be visualized by fluorescence microscopy.  
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Figure 3.2. Endogenous RanBPM and c-Raf are found in a complex. An in situ 
PLA was performed in (A) HeLa control cells, without the addition of primary 
antibodies (negative control); (B) HeLa 2-7 cells, using primary antibodies against c-
Raf and RanBPM (negative control); (C) HeLa control cells, using primary antibodies 
against Hsp90 and RanBPM (positive control); (D) HeLa control cells, primary 
antibodies against using c-Raf and RanBPM. DAPI staining was used to visualize 
the nuclei at 358nm, while the PLA dots representing protein-protein interactions 
were visualized at 555nm.  
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Given that c-Raf is known to interact with Hsp90 (96), a positive control 
was included where HeLa control cells were incubated with antibodies against c-
Raf and Hsp90. This did expectedly produce fluorescent dots representing 
interactions (Figure 3.2C). In HeLa control cells in which antibodies against c-Raf 
and RanBPM were included for the assay, fluorescent dots were observed, 
confirming that the two endogenously expressed proteins are found together in a 
complex (Figure 3.2D). 
 
3.2. The N-terminus, CRA and LisH/CTLH domains of RanBPM are required 
for c-Raf downregulation 
 
Previous experiments in our laboratory have also demonstrated that 
RanBPM downregulates c-Raf at the protein level (24). Given that RanBPM 
contains a number of conserved domains, we strove to determine which regions 
of RanBPM were necessary for downregulation of c-Raf. In order to achieve this, 
we used a series of RanBPM deletion mutant constructs (Figure 3.3), which have 
been cloned into the mammalian expression vector pCMV-HA (18,103), to test 
their effects on levels of ΔN c-Raf. ΔN c-Raf, a constitutively active construct of 
c-Raf containing only amino acids 325-648 (82), was used instead of full-length 
c-Raf because RanBPM has been shown to have a greater effect on activated c-
Raf (24). By using this construct, we allowed ourselves to observe the most 
pronounced effect of each RanBPM deletion mutant on c-Raf levels, enabling us 
to better discern which mutants have lost their ability to downregulate c-Raf. 
Furthermore, since RanBPM is able to dimerize (13), we opted to perform our 
experiments in HeLa 2-7 cells to avoid dimerization between mutant RanBPM 
and endogenous WT RanBPM monomers. Thus, in our system, HeLa 2-7 cells 
were transfected with pEBG-GST-ΔN-c-Raf as well as either pCMV-HA vector, 
pCMV-HA-RanBPM or a pCMV-HA RanBPM deletion mutant. Cell extracts were 
prepared and the effect of each RanBPM mutant on levels of c-Raf was analyzed 
by Western blot. 
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Figure 3.3. Full-length RanBPM and deletion mutants chosen for analysis. WT, 
ΔN2, ΔC4, ΔC1, Δ212, and Δ360 RanBPM constructs were cloned into the 
mammalian expression vector pCMV-HA.  
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As previously reported (24), WT RanBPM was able to significantly 
downregulate ΔN c-Raf compared to the levels of ΔN c-Raf seen in the pCMV-
HA control, resulting in a 2.08 ± 0.44 fold decrease of ΔN c-Raf expression 
(Figures 3.4A-D). Furthermore, Δ212 RanBPM was also able to downregulate 
ΔN c-Raf compared to the levels of ΔN c-Raf seen in the pCMV-HA control, 
demonstrating a significant 1.58 ± 0.45 fold decrease of ΔN c-Raf expression 
(Figures 3.4A and 3.4C). Although it would appear from the representative image 
that Δ212 RanBPM was able to downregulate ΔN c-Raf better than WT RanBPM, 
Δ212 RanBPM actually demonstrated better expression in this experiment and 
therefore more protein was likely available to exert its effect on ΔN c-Raf (Figure 
3.4A). Overall, the effects that Δ212 RanBPM and WT RanBPM demonstrated on 
ΔN c-Raf were not significantly different from one another (Figure 3.4C), 
indicating that the SPRY domain is not required for c-Raf destabilization. 
ΔN2 RanBPM, however, was unable to effectively downregulate ΔN c-Raf 
and resulted in a significant 3.14 ± 0.60 fold increase when compared to the 
levels of ΔN c-Raf seen in response to WT RanBPM (Figures 3.4A and 3.4C). 
ΔN c-Raf expression in response to this mutant was not significantly different 
than that observed in the pCMV-HA control (Figure 3.4A and 3.4C). The 
expression of ΔN2 RanBPM is consistently much lower than that of the other 
RanBPM deletion mutants, despite identical transfection conditions, and thus our 
laboratory has hypothesized that the protein is very unstable (16,18). Despite this 
phenomenon, levels of ΔN2 RanBPM near those of WT RanBPM were achieved 
in this experiment (Figure 3.4A) and therefore it is reasonable to conclude that 
ΔN2 RanBPM has lost its ability to downregulate ΔN c-Raf. This implies that the 
N-terminus of RanBPM is required for its effect on c-Raf. 
Δ360 and ΔC4 RanBPM also did not effectively downregulate ΔN c-Raf, 
as ΔN c-Raf expression levels were significantly higher than those seen in 
response to WT RanBPM, demonstrating 4.68 ± 1.15 and 3.34 ± 0.71 fold 
increases respectively, and were not significantly different than those seen in the 
pCMV-HA control (Figures 3.4A and 3.4C).  This occurred despite the fact that 
expression of these mutants was remarkably higher than that of WT RanBPM. 
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Figure 3.4. Δ360, ΔN2, ΔC4 and ΔC1 RanBPM deletion mutants do not 
effectively downregulate ΔN c-Raf compared to WT RanBPM. HeLa 2-7 cells 
were transfected with pEBG-GST-ΔN-c-Raf and either pCMV-HA, pCMV-HA-
RanBPM or pCMV-HA RanBPM deletion mutant constructs. Extracts were analyzed 
by Western blot. (A,B) Representative images are shown. (C,D) Multiple 
experiments were quantified by normalizing ΔN c-Raf levels to the loading control, β-
actin, and statistical analyses were performed (N 4–25, SEM shown).  
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These results suggest that the LisH/CTLH domains and the C-terminus of 
RanBPM play a role in c-Raf downregulation. However, considering that the ΔC4 
deletion removes a very large portion of RanBPM, we decided to repeat the 
experiment using a construct harboring only a deletion of the CRA domain, 
namely the ΔC1 RanBPM construct. ΔC1 RanBPM behaved nearly identically to 
ΔC4 RanBPM in its inability to downregulate ΔN c-Raf and resulted in a 3.76 ± 
1.15 fold increase when compared to the levels of ΔN c-Raf seen in response to 
WT RanBPM, (Figures 3.4B and 3.4D). This implies that within the C-terminus of 
RanBPM, it is specifically the CRA domain that is needed for c-Raf 
downregulation. 
Altogether, these results demonstrate that the N-terminus, LisH/CTLH and 
CRA domains are required for c-Raf destabilization, since loss of any of these 
regions render RanBPM unable to effectively downregulate c-Raf. 
 
3.3. The CRA domain of RanBPM is required for interaction with c-Raf 
 
To continue to characterize the interaction between RanBPM and c-Raf, 
we aimed to determine the domain or domains of RanBPM required for the 
interaction. To accomplish this, we used the same system outlined in section 3.2 
and used the extracts to perform GST pull-down assays to test which RanBPM 
deletion mutants have retained their ability to interact with ΔN c-Raf. 
Specifically, HeLa 2-7 cells were transfected with either pEBG-GST and 
pCMV-HA-RanBPM, or pEBG-GST-ΔN-c-Raf and either pCMV-HA-RanBPM or a 
pCMV-HA RanBPM deletion mutant. Due to its poor stability, ΔN2 RanBPM was 
not among the mutants tested as we were unable to obtain sufficient levels of the 
protein to detect it in this type of assay. Cell extracts were prepared and 
Glutathione-Agarose beads were incubated with the resulting extracts to pull-
down GST or GST-ΔN-c-Raf, as well as any RanBPM deletion mutant associated 
with it. Pull-down samples were analyzed by Western blot. 
As anticipated based on previous studies (24), GST-ΔN-c-Raf was able to 
successfully pull-down WT RanBPM in the positive control, while, as expected for 
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the negative control, GST alone only pulled-down background levels of WT 
RanBPM (Figures 3.5A-C). Δ212 RanBPM and Δ360 RanBPM both retained 
their abilities to interact with ΔN c-Raf, as levels of pulled-down RanBPM were 
not significantly different than those of the positive control but were significantly 
higher than those of the negative control (Figures 3.5A-C). This indicates that the 
SPRY and LisH/CTLH domains are not required for the interaction between 
RanBPM and c-Raf, since deletion of these regions does not nullify the 
interaction. 
However, ΔC1 RanBPM was not able to effectively interact with ΔN c-Raf, 
as the amount of ΔC1 RanBPM associating with ΔN c-Raf resulted in a 
significant 2.12 ± 0.19 fold decrease compared to the amount of WT RanBPM 
associating with ΔN c-Raf, but was not significantly different than the level of 
interaction seen in the negative control (Figures 3.5A and 3.5C). Altogether, this 
data suggests that the CRA domain is the only domain tested that appears to be 
required for the interaction between RanBPM and c-Raf, since deletion of this 
region abolishes the interaction. 
 
3.4. RanBPM interacts directly with c-Raf through the CRA domain 
 
Further tests were needed to confirm the interaction between the CRA 
domain of RanBPM and c-Raf. Also, the nature of the interaction, whether it be 
direct or mediated by another factor, remained to be determined. Therefore, to 
address this matter, we aimed to repeat pull-down experiments using bacterial 
extracts. By expressing our mammalian RanBPM and c-Raf constructs in E. coli, 
we ensured that no other mammalian proteins were present to mediate the 
interaction between our two proteins of interest. Thus, if the interaction was to 
persist in this system, it was assumed to be direct. 
We opted to clone individual domains of RanBPM, as well as WT 
RanBPM, downstream of GST into the bacterial expression vector pGEX-4T-1 
(Figure 3.6). In addition to testing the C1 domain, consisting only of the CRA 
domain, we took advantage of this relatively simple system to also test the N2 
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 Figure 3.5. ΔC1 RanBPM is unable to interact effectively with ΔN c-Raf. HeLa 2-
7 cells were transfected with either pEBG-GST and pCMV-HA-RanBPM or pEBG-
GST-ΔN-c-Raf and either pCMV-HA-RanBPM or a pCMV-HA RanBPM deletion 
mutant. A GST pull-down assay was performed on the resulting extracts and pull-
downs were analyzed by Western blot. (A,B) Representative images are shown. (C) 
Multiple experiments were quantified by normalizing RanBPM mutant levels to 
pulled-down GST or GST-ΔN-c-Raf and statistical analyses were performed (N 4–9, 
SEM shown). 
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Figure 3.6. Full-length RanBPM and individual domains chosen for analysis. 
WT RanBPM, N2 domain and C1 domain were cloned into the bacterial expression 
vector pGEX-4T-1.  
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domain, which remained unexamined due to the poor level of expression of the 
ΔN2 RanBPM deletion mutant in previously conducted mammalian cell-based 
GST pull-down assays (Figure 3.5). 
Each GST-tagged construct, as well as GST alone, was expressed 
separately in E. coli and purified using Glutathione-Agarose beads. These 
constructs were each subsequently incubated with a crude cell lysate from E. coli 
expressing ΔN c-Raf. The GST-tagged constructs were pulled-down and 
analyzed by Western blot to detect levels of associated ΔN c-Raf.  
Both GST-WT-RanBPM and GST-C1 were able to pull-down ΔN c-Raf 
significantly above background levels pulled down by GST alone, demonstrating 
5.02 ± 0.98 and 2.71 ± 0.36 fold increases, respectively (Figures 3.7A and 3.7B). 
Although it appears that WT RanBPM associates with ΔN c-Raf better than the 
C1 domain does, the variability within the levels of ΔN c-Raf pulled-down with 
WT RanBPM was relatively high and in fact the amount of ΔN c-Raf pulled-down 
with WT RanBPM is not significantly different than that pulled-down with the C1 
domain (Figure 3.7B). Therefore, this result confirms that the CRA domain of 
RanBPM is able to interact with c-Raf and the interaction between RanBPM and 
c-Raf is direct. 
GST-N2, unlike GST-WT-RanBPM and GST-C1, was unable to pull-down 
ΔN c-Raf significantly better than GST alone (Figures 3.7A and 3.7B). This 
suggests that the N-terminus of RanBPM is unable to directly interact with c-Raf, 
although an indirect interaction cannot be ruled out based on these results. 
 
3.5. Endogenous c-Raf and MAEA are found in a complex 
 
Since only the CRA domain of RanBPM is able to interact with ΔN c-Raf 
but multiple domains play a role in regulating its levels, it is likely that RanBPM is 
interacting with another protein or complex in order to downregulate ΔN c-Raf. A 
possible candidate is the CTLH complex, a potential E3 ubiquitin ligase complex 
which has been shown to include RanBPM and could function to target c-Raf for 
proteasomal degradation (46,47). For this reason, a PLA was performed to 
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 Figure 3.7. WT RanBPM and C1 domain interact directly with ΔN c-Raf. GST 
pull-down assays were performed using GST, GST-WT-RanBPM, GST-N2-domain 
and GST-C1-domain E. coli extracts as well as ΔN c-Raf E. coli extracts. Pull-downs 
were analyzed by Western blot. (A) A representative image is shown. (B) Multiple 
experiments were quantified by normalizing ΔN c-Raf levels to pulled-down GST, 
GST-WT-RanBPM, GST-N2 or GST-C1 and statistical analyses were performed (N 
6, SEM shown).  
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investigate whether MAEA, a CTLH complex protein, is able to form a complex 
with c-Raf.  
As expected, interactions were not seen in the negative control, namely 
HeLa cells in which primary antibodies were not added (Figure 3.8A). Since 
MAEA and RanBPM are known to be found together within the CTLH complex 
(42,46), a positive control was performed in HeLa cells using primary antibodies 
against MAEA and RanBPM. Interactions were indeed seen in this positive 
control (Figure 3.8B). In HeLa cells in which primary antibodies against MAEA 
and c-Raf were added, interactions were observed, although in noticeably fewer 
numbers than the positive control (Figure 3.8C). This evidence suggests that 
endogenous c-Raf does form a complex with MAEA and could associate with the 
CTLH complex as a whole. 
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Figure 3.8. Endogenous MAEA and c-Raf are found in a complex. An in situ PLA 
was performed in HeLa cells (A) without the addition of primary antibodies (negative 
control), (B) using primary antibodies against MAEA and RanBPM (positive control) 
and (C) using primary antibodies against MAEA and c-Raf. DAPI staining was used 
to visualize the nuclei at 358nm, while the PLA dots representing protein-protein 
interactions were visualized at 647nm.  
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Chapter 4 – Discussion 
 
4.1. Summary of findings 
 
The aim of this study was to characterize the interaction between 
RanBPM and c-Raf. We hypothesized that specific domains of RanBPM are 
required for direct interaction with c-Raf and regulation of c-Raf stability by a 
mechanism involving the CTLH complex. Specifically, we sought to determine 
which domain(s) of RanBPM are required for regulation of c-Raf stability, identify 
which domain(s) of RanBPM are required for interaction with c-Raf and 
investigate the mechanism by which RanBPM downregulates c-Raf. In summary, 
we found that RanBPM and c-Raf in fact do form a complex in cells. The N-
terminus, CRA domain and LisH/CTLH domains of RanBPM are required for 
downregulation of c-Raf but only the CRA domain is required for complex 
formation with c-Raf (Table 4.1). RanBPM interacts directly with c-Raf and the 
CRA domain is sufficient for this direct interaction to occur. Finally, the CTLH 
complex member MAEA and c-Raf are also found together in a complex, 
suggesting that c-Raf could associate not only with RanBPM and MAEA, but with 
the entire CTLH complex. 
 
4.2. Model and rationale 
 
Based on the results obtained from this study, we propose a mechanism 
by which RanBPM downregulates c-Raf (Figure 4.1). Since deletion of the CRA 
domain of RanBPM was sufficient to abolish the interaction between RanBPM 
and c-Raf and since the CRA domain alone was shown to be able to interact 
directly with c-Raf, it has become evident that RanBPM interacts directly with c-
Raf through its CRA domain. Deletion of the CRA domain also prevented c-Raf 
downregulation, presumably as c-Raf was no longer tethered to the protein 
regulating its stability. Deletion of the LisH/CTLH domains also inhibited c-Raf 
downregulation, however RanBPM still retained its ability to interact with c-Raf. 
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Table 4.1. Summary of results of the effects of RanBPM constructs on 
downregulation of ΔN c-Raf and interaction with ΔN c-Raf.    
 
RanBPM construct Downregulates ΔN c-Raf Interacts with ΔN c-Raf 
WT RanBPM YES YES 
Δ212 RanBPM (ΔSPRY) YES YES 
ΔC4 RanBPM (ΔC-terminus) NO NO 
ΔC1 RanBPM (ΔCRA) NO NO 
Δ360 RanBPM (ΔLisH/CTLH) NO YES 
ΔN2 RanBPM (ΔN-terminus) NO ND 
C1 domain (CRA) ND YES 
N2 domain (N-terminus) ND NO 
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Figure 4.1. Model of the mechanism by which RanBPM downregulates c-Raf. 
RanBPM directly interacts with c-Raf via its C-terminal CRA domain and presumably 
interacts with another protein or protein complex, such as the CTLH complex, via its 
LisH/CLTH domain to downregulate c-Raf.  
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Therefore, it is hypothesized that some other protein or protein complex is 
interacting with RanBPM through its LisH/CTLH domains to downregulate c-Raf. 
Deletion of the N-terminus of RanBPM also resulted in a loss of c-Raf 
downregulation and this region was also shown to be unable to interact directly 
with c-Raf. Therefore, the N-terminus might aid the LisH/CTLH domains in 
mediating the interaction between RanBPM and the unidentified complex 
potentially responsible for downregulating c-Raf. This is plausible since the N-
terminus is a potentially flexible proline-rich region of RanBPM which could fold 
over to stabilize the protein or, in this case, stabilize interactions with other 
proteins (16). Given that deletion of the SPRY domain did not perturb the ability 
of RanBPM to downregulate or interact with c-Raf, we propose that this domain 
does not participate in regulation of c-Raf. 
 We have presented a plausible mechanism which suggests the 
involvement of an additional protein or protein complex in the downregulation of 
c-Raf. We propose that c-Raf might be targeted for degradation by the CTLH 
complex in a RanBPM-dependent manner, with c-Raf being tethered to the 
complex by RanBPM through its CRA domain, and that the CTLH complex 
interacts with RanBPM primarily through its LisH/CTLH domains. RanBPM is a 
known member of the CTLH complex and our results show that c-Raf can 
associate with both RanBPM and MAEA, another member of the CTLH complex. 
This mammalian complex is comprised of six proteins in total, all of which have 
known orthologs in S. cerevisiae that form the yeast Gid complex (6). Given that 
the Gid complex is a proven E3 ubiquitin ligase, it has been hypothesized that 
the CTLH complex may play a similar role in mammalian cells (6). Though this 
has not experimentally been shown, we propose that the CTLH complex may 
play a role in the ubiquitination and degradation of target proteins and that it may 
be targeting c-Raf for degradation in a mechanism that depends on RanBPM as 
a scaffold for the complex. While the topology of the mammalian CTLH complex 
has not been elucidated, the idea that RanBPM may act as a scaffold in the 
complex is consistent with previous studies. It has been shown that Gid1, the 
yeast ortholog of RanBPM, acts as a scaffold for the Gid complex and interacts 
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with other members of the complex mainly through its LisH and CTLH domains 
(47).  
 Although the major piece of evidence in our study tying the CTLH complex 
to c-Raf downregulation is the fact that c-Raf and MAEA associate in cells, 
subtleties in our data are also consistent with the idea that the CTLH complex 
may be involved in c-Raf downregulation. The number of interactions seen 
between c-Raf and MAEA were noticeably fewer than the number of interactions 
seen in the positive control between RanBPM and MAEA. This is compatible with 
the idea that RanBPM and MAEA are fixed members of the CLTH complex, 
whereas c-Raf may only associate with the complex temporarily to target it for 
degradation. Also, previous studies in our laboratory have shown that RanBPM 
has a greater effect on the active form of c-Raf, which represents only a fraction 
of the total pool of endogenous c-Raf in the cell (24). This further supports the 
observation that c-Raf associates with MAEA infrequently, as only activated c-
Raf may be targeted for degradation by RanBPM, MAEA and the rest of the 
CTLH complex. 
A large number of studies have described proteins that interact with 
RanBPM, albeit they seldom provide functional significance for the interactions. A 
number of these interacting proteins have been described in Chapter 1, but a 
broader record has been retrieved from the BioGRID (Biological General 
Repository for Interaction Datasets) version 3.2.114 (Figure 4.2) (105). In 
addition to the evidence discussed in Chapter 1 of ARMc8, Rmnd5a and MAEA 
being involved in ubiquitination, the collection of proteins retrieved from the 
BioGRID that interact with RanBPM involved in ubiquitination, deubiquitination, 
ubiquitin-like modification or management of ubiquitinated proteins give further 
weight to the argument that RanBPM and the CTLH complex may play a role in 
these processes. 
For example, RanBPM has been shown to interact with the essential 
aggresome component HDAC6 (histone deacetylase 6) (Figure 4.2) and our 
laboratory has shown that RanBPM is essential for aggresome formation (103). 
Aggresomes are perinuclear structures that accommodate ubiquitinated, 
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Figure 4.2. RanBPM interactome retrieved from the BioGRID version 3.2.114 
showing 71 proteins that interact with human RanBPM. Interactions between 
RanBPM and other proteins are connected by a red line and interactions between 
RanBPM interacting partners are connected by a blue line. CTLH complex members 
are outlined in purple and proteins involved in ubiquitination, deubiquitination, 
ubiquitin-like modification and management of ubiquitinated proteins are outlined in 
green.  
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misfolded or damaged proteins in conditions where the proteasome and the UPS 
are overwhelmed (106). This crucial role in aggresome formation implies that 
RanBPM has the ability to handle ubiquitinated proteins targeted for degradation. 
In addition, RanBPM has been found to interact with the E3 ubiquitin ligase 
TRAF6 (tumor necrosis factor-receptor-associated factor 6) (Figure 4.2) and to 
reduce the TGF-β (transforming growth factor β) dependent auto-ubiquitination of 
TRAF6 (107). Some high-throughput screens studying the ubiquitinome have 
even found RanBPM among a pool enriched for ubiquitinated proteins (Figure 
4.2) (108). This may simply be evidence of RanBPM itself being targeted for 
ubiquitination, given that RanBPM has been shown to be ubiquitinated as well as 
deubiquitinated specifically through interaction with USP11 (ubiquitin-specific 
protease 11) (Figure 4.2) (109). However, there is still substantial reason to 
suspect that RanBPM, in concert with the CTLH complex, could be playing a role 
in protein ubiquitination and subsequent degradation by the proteasome.  
 Although we now propose the CTLH complex as the complex potentially 
responsible for interacting with RanBPM to downregulate c-Raf, during the 
course of this study we initially investigated other proteins and complexes which 
we thought may be playing this role. Initially, we attempted to investigate Hsp90 
as a potential c-Raf regulatory mechanism in this context. Hsp90 is a well-
characterized molecular chaperone which has been shown to bind and stabilize 
c-Raf, allowing it to properly participate in ERK pathway signaling (94-96). Since 
previous results in our laboratory have shown that downregulation of c-Raf by 
RanBPM inhibits further ERK pathway signaling and that RanBPM expression 
disrupts complex formation between c-Raf and Hsp90, we hypothesized that 
RanBPM might be preventing Hsp90 from stabilizing c-Raf (24). However, we 
were unable to obtain further conclusive evidence of altered acetylation of 
Hsp90, which reflects Hsp90 activity, in response to RanBPM expression (data 
not shown). Furthermore, previous preliminary experiments in our laboratory 
showed no evidence of E3 ubiquitin ligase CHIP complex formation with 
RanBPM and c-Raf, suggesting CHIP is not involved in the downregulation of c-
Raf by RanBPM. Although other studies have shown that CHIP is able to 
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ubiquitinate c-Raf and send it for proteasomal degradation, it has also been 
suggested that c-Raf may be ubiquitinated and degraded by CHIP-independent 
mechanisms (98-100).  
 
4.3. Significance of the CRA domain as a binding-domain for c-Raf 
 
 Many studies have identified binding partners for RanBPM and suggested 
roles for the protein in various cellular processes, but a clear function for 
RanBPM has yet to be elucidated. Our study further contributes to our growing 
knowledge of the protein and demonstrates the importance of the CRA domain of 
RanBPM for its interaction with c-Raf. Some studies have already identified 
certain regions of RanBPM to be required for interactions with specific proteins. 
For example, the SPRY domain of RanBPM has been shown to be required for 
interaction with CDK11p46, L1, MET, TrkA, AR and USP11 (7,8,20,25,35,109). 
The SPRY domain, along with the LisH domain, has been shown to be sufficient 
for interaction with BACE1, LRP and APP to increase Aβ generation (29). The 
LisH and CTLH domains have both been shown to be required for RanBPM 
interaction with HDAC6 and only FMRP has previously been shown to interact 
with the CRA domain of RanBPM (14,103). Our study defines c-Raf as only the 
second protein to be found to interact with RanBPM through the CRA domain 
and further confirms this domain to be a protein interaction surface. 
 The CRA domain has only been reported in a small number of proteins 
other than RanBPM, namely RanBP10 (Ran-binding protein 10), MAEA, 
Rmnd5a, Rmnd5b and Twa1 (46,110). It has not been shown, but there is 
potential for c-Raf to interact with the CRA domain of these proteins as well, 
although most of these proteins are found within the CTLH complex. RanBP10, 
the only non-CTLH complex member, shows very high sequence similarity to 
RanBPM and has also been named for its supposed ability to interact with Ran 
(110). The CRA domain has been predicted to contain six alpha-helices, and 
thus has been hypothesized to resemble a DD superfamily domain (14). DD 
superfamily proteins are generally proteins that propagate apoptotic signals, such 
57
  
as the death receptors p75NTR and Fas as well as a number of caspases (111). 
Although c-Raf signaling affects the activities of many downstream proteins 
involved in apoptosis, an extensive literature search did not reveal any c-Raf 
interacting partners containing a DD superfamily domain. Thus, this study 
appears to uncover a novel binding domain for c-Raf, as interacting partners 
containing a CRA domain or a DD superfamily domain have not yet been 
reported.  
 However, it is possible that c-Raf interacts specifically with a sub-section 
of the CRA domain, such as with the surface of a particular helix, rather than with 
the entire domain. c-Raf has in fact been shown to interact with the surface of 
helices in other proteins. For example, residues lysine 49, arginine 56 and 
arginine 60 along the surface of helix 3 in the protein 14-3-3 have been shown to 
be important for interaction with c-Raf (112). Although residues on helices often 
contribute the binding surface for protein-protein interactions, the details of the 
direct interaction between c-Raf and the CRA domain remain to be examined. 
 
4.4. Consequences of RanBPM-mediated regulation of c-Raf 
 
 This study also further contributes to our knowledge of c-Raf regulatory 
mechanisms within mammalian cells. Although our evidence of RanBPM-
dependent CTLH complex downregulation of c-Raf is preliminary, the 
consequences of this potential novel regulatory mechanism are impactful. As 
previous work in our laboratory has shown, loss of c-Raf has serious downstream 
signaling effects, as RanBPM-mediated downregulation of c-Raf and consequent 
inhibition of the ERK pathway leads to decreased levels of the anti-apoptotic 
proteins Bcl-2 and Bcl-XL (24). However, ERK1/2 has over 150 other 
downstream signaling proteins and thus RanBPM-mediated destabilization of c-
Raf could affect any number of these signaling pathways and associated cellular 
processes (54,66). c-Raf is also implicated in non-ERK pathway signaling, such 
as its negative regulation of the pro-apoptotic proteins ASK1 and MST2 (72,73). 
Though this has not been shown, RanBPM could partially exert its apoptotic 
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activity by protecting levels of ASK1 and MST2 through c-Raf downregulation. 
Altogether, through multiple downstream effectors, c-Raf dictates a number of 
cellular processes, such as differentiation, proliferation, motility and apoptosis 
(54,55). Therefore its RanBPM-dependent regulation is a crucial factor in 
ensuring these functions are properly executed. 
 c-Raf regulation has long been regarded as a target for cancer 
therapeutics, since the ERK pathway is known to be upregulated in over one-
third of all human cancers (56). Numerous drugs have been developed in an 
attempt to combat Raf activity and increase tumour cell apoptosis, but drug 
resistance remains an obstacle and combination drug therapy is often employed 
to increase the chance of success. Given that RanBPM demonstrates tumour 
suppressor activity, a RanBPM-derived cancer therapeutic could prove useful 
and add diversity to the growing number of Raf inhibitors used in the clinic. In 
addition to the previously mentioned work showing that RanBPM inhibits cell 
survival and migration, preliminary data from our laboratory provides further 
evidence of RanBPM as a crucial tumour suppressor (24). Immunocompromised 
mice injected with RanBPM-deficient HEK cells showed significantly increased 
tumour formation, primarily localized in the liver, compared to mice injected with 
HEK cells expressing RanBPM (113). In addition, mouse embryonic fibroblasts 
generated from RanBPM knockout mice bred in our laboratory showed increased 
levels of c-Raf compared to those generated from WT mice (113). This provides 
significant relevance to the concept of c-Raf regulation by RanBPM, as this event 
has now been shown in a model that closely mimics human physiology. 
 
4.5. Limitations of the study and future studies 
 
 Although the work presented in this thesis yielded informative results, 
some limitations were encountered which could be taken into consideration when 
planning future studies. Primarily, it was very difficult to obtain even expression of 
RanBPM deletion mutants upon transfection in HeLa cells in order to fairly asses 
the ability of each mutant to downregulate c-Raf. Given that RanBPM deletion 
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mutants exhibit levels of stability different from one another, the amount of DNA 
used for the transfection of each mutant construct had to be adjusted to obtain 
similar levels of protein expression among all mutants. However, despite careful 
optimization, the expression of RanBPM deletion mutants still varied somewhat. 
Even expression might have been achieved with the generation of HeLa cell lines 
stably expressing each RanBPM deletion mutant construct. This project remains 
ongoing in the laboratory. 
 Furthermore, based on the presence or absence of NLS or NES signals 
within the sequence of each RanBPM deletion mutant, the subcellular 
localization of certain mutants could have been altered and hindered their ability 
to downregulate c-Raf, a predominantly cytoplasmic protein. For example, both 
Δ212 and Δ360 RanBPM demonstrate increased nuclear localization (16). 
Therefore, 60–70% of the total protein is in fact sequestered within the nucleus 
and unable to interact with c-Raf, although 30–40% is still nucleocytoplasmic and 
able to participate in c-Raf regulation (16). Given that Δ212 RanBPM is mostly 
nuclear but still demonstrates a strong ability to regulate c-Raf, it is presumed 
that similar cytoplasmic levels of Δ360 RanBPM would have also demonstrated 
this effect if the protein was fully functional in this aspect. 
 It is also important to note that large protein deletions can have a 
significant negative impact on the proper folding and stability of a protein. This 
phenomenon was exemplified perfectly in this study in the case of the ΔN2 
RanBPM mutant, where deletion of the N-terminus of the protein resulted in 
decreased expression, presumably due to protein instability. Although this type of 
instability was not seen for the other RanBPM deletion mutants, it is difficult to 
predict whether deletion of the SPRY domain, LisH/CTLH domains or C-terminus 
resulted in misfolding of RanBPM. If this was the case, it would be impossible to 
distinguish if the results obtained were in fact due to lack of a required functional 
domain or simply due to misfolding of the protein. Generating point mutations 
inhibiting the function of a specific domain is generally a more cautious approach 
when conducting these types of studies, however given a lack of knowledge on 
the key residues within each domain of RanBPM, this strategy could not be 
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employed here. However, future studies could focus on locating specific residues 
within the CRA domain of RanBPM that abolish its interaction with c-Raf. 
Subsequent experiments using this mutant could give a more reliable idea of the 
effect of loss of interaction between RanBPM and c-Raf, since RanBPM folding 
would be less likely to be affected by a simple point mutation. 
 Other key future studies include continuing to explore the idea of CTLH 
complex involvement in RanBPM-mediated c-Raf downregulation. It would be 
important to provide evidence of RanBPM-dependent c-Raf ubiquitination or 
proteasomal degradation, although this was attempted during the course of this 
study and no conclusive evidence was obtained (data not shown). It would also 
be intriguing to knock-down expression of various CTLH complex members in 
cells and investigate the effect on c-Raf. Since shRNA knock-down of RanBPM 
leads to increased levels of c-Raf, knocking-down a CTLH complex member 
would be expected to yield similar results. Altogether, this would further support 
the hypothesis that the CTLH complex is involved in c-Raf regulation. 
 
4.6. Conclusion 
 
 Overall, this thesis aimed to characterize the interaction between two 
important regulators of key cellular processes, RanBPM and c-Raf. Although the 
role and importance of c-Raf has been well-documented in the past, the exact 
function of RanBPM remains an enigma and ongoing research in the fields of 
cancer and neurological disease aims to better understand this protein. The work 
presented in this thesis not only contributes to our knowledge of RanBPM, but 
also clarifies the relationship between RanBPM and c-Raf by proposing a novel 
model regarding how RanBPM downregulates c-Raf. Such knowledge is critical 
in understanding RanBPM as a tumour suppressor and regulator of the ERK 
pathway, a pathway known to be heavily involved in human oncogenesis. 
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